Landing
Retina World Congress (RWC) 2025
24-Month Results from GALE Open-Label Extension: Efficacy and Safety of 48 Months of Continuous Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration
AREDS Oral Micronutrient Supplementation Impact on Geographic Atrophy Progression: Insights from the Phase 3 OAKS and DERBY Trials
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.